HDC is approved in Europe, in conjunction with low-dose IL-2, for relapse prevention in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after chemotherapy [18]. This evidence concerns the gene IL2 and acute myeloid leukemia.